I. What is CIK cell? CIK” is the abbreviation of “cytokine induced killer”, and the Chinese translation of “CIK cells” is “cytokine induced killer cells”. CIK cells are a type of cell population produced from peripheral blood mononuclear cells in vitro by co-induction of various cytokines, which have significant anti-pathogen and anti-tumor activities. Second, CIK cells anti-tumor, anti-tuberculosis mechanism of action and characteristics CIK cells can identify tumor cells and tuberculosis infected cells, through contact with tumor cells directly kill the tumor or secrete a variety of anti-tumor and anti-tuberculosis cytokines to inhibit tumor growth and bacterial replication. At the same time, the cytokines secreted by CIK cells can also effectively activate the body’s immune system and improve the patient’s own anti-tumor and anti-tuberculosis ability. CIK cell therapy is currently an effective solution for anti-tumor and anti-tuberculosis secondary immunotherapy, which has the following characteristics: CIK cells proliferate rapidly, have strong anti-tumor and antiviral activity, have a broad tumor killing spectrum, and have no toxic effects on normal cells. Since CIK cells are derived from the patient’s own peripheral blood mononuclear cells, they will not produce rejection and other reactions, and are very safe to apply. Third, CIK cell therapy for tuberculosis and tumor indications cardiac, cerebrovascular disease, hypertension, diabetes, renal insufficiency or failure and autoimmune disease patients should not use CIK cell therapy. Others, such as long-term use of immunosuppressive drugs after organ transplantation, use of immunosuppressive drugs, systemic chemotherapy for less than 2 weeks, definite infection or fever, are also not suitable for CIK cell therapy. IV. What is the procedure of CIK cell therapy? Liver function, blood routine, coagulation function, etc. will be checked before treatment. If the basic conditions are met, CIK cell therapy can be performed after signing the informed consent form. The cells are first collected from the patient’s peripheral blood using a component blood separator, and then cultured in a GMP laboratory for approximately 10 days. On the 10th day of culture, CIK cells are returned in three infusions, each at an interval of 1 to 2 days, so that a course of treatment lasts approximately 14 to 16 days. Depending on the treatment status, the next course of treatment can be carried out at an interval of 4 to 6 months. V. What should I pay attention to before and during cell collection? Patients can eat and drink normally before cell collection, but do not eat greasy food or eat too much. Some patients may experience numbness in the mouth, face and limbs during the cell collection process, which can disappear with oral calcium gluconate. In weak individuals, the collection time may be extended appropriately. VI. Do I need to be hospitalized for CIK cell therapy? What is the procedure for hospitalization? Depending on the patient’s condition and treatment, CIK cell therapy can be performed as an inpatient or outpatient. 7.What are the adverse effects of CIK cell therapy? CIK cells are derived from the patient’s own cells, so the treatment is very safe. About 80% of patients have a febrile reaction after cell transfusion, with body temperature ranging from 37.2℃ to 38.5℃, and most of them return to normal body temperature within 2-6 hours. In a very small number of cases, the body temperature is higher than 39.5°C. Physical cooling or antipyretic drugs can be used, but do not use hormonal drugs. No other serious adverse reactions have been seen.